The consulting and research company Frost & Sullivan, which awarded the award, stated: "The development of Biundwax makes it possible to overcome the limitations of the seasonal vaccines that exist today"
In recent years, with the emergence of worldwide influenza pandemics, it has been proven once again that influenza has a significant impact on the lives of millions of people around the world. The influenza virus is exposed to many changes (mutations) in its protein sequence, therefore, the new viruses that appear every year are not recognized by the immune system and it is necessary to prepare a new vaccine every year. The existing vaccine protects against the viruses contained in it and is not suitable for all the new mutations, therefore it is necessary to vaccinate the population before each flu season. In addition, the seasonal vaccines are produced using expensive methods, which require time and are not always effective.
The development of Biondvax aims to overcome the limitations of seasonal vaccinations that exist today. The company is developing a vaccine based on the common denominator of all influenza viruses, which can therefore activate the immune system against all existing and future variations of the influenza virus. The vaccine is based on research conducted by Prof. Ruth Arnon for about 15 years at the Weizmann Institute and continued at Biondvax since the start of operations in 2005.
The multimeric vaccine has three characteristics that set it apart from the existing flu vaccines and from other universal vaccines that are in development stages: First, it stimulates the two arms of the immune system: the antibody arm and the cellular arm, thus significantly increasing the ability to deal with the disease. Second, the vaccine is based on conserved regions in influenza virus type A and type B and should therefore protect against all types of influenza virus both seasonal and pandemic. In addition, the production of the vaccine is done in a short and simple process that lasts about 6-8 weeks and this is compared to the production of vaccines in eggs or cell cultures that last about 4-6 months.
Compared to the current vaccines for seasonal flu, the universal vaccine developed by Biondvax can be taken once every 3-5 years as it is expected to provide long-term protection against the virus.
The effectiveness of the vaccine has been proven in laboratory animals and recently, the Biondvax company has successfully completed two phase II/I clinical trials in humans, young and old, in both of which the vaccine was found to be safe to use. In addition, the vaccine activated the two arms of the human immune system - the antibody arm and the cellular arm. In light of these successes, the company continued with the clinical program and in the coming months a phase IIa trial in humans with the multimeric vaccine will begin. The results of this experiment are expected to be received in the middle of 2011.
"Bionvax is happy to receive this prestigious award from Frost & Sullivan," said Dr. Ron Babkov CEO of Bionvax, "We believe in the news of innovation that our universal flu vaccine brings with it. This vaccine has the potential to significantly change the way we protect ourselves against Influenza and it's not just a matter of protection against the seasonal virus, but an effective vaccine against both seasonal and pandemic flu."
The Frost & Sullivan Innovation Award is awarded each year to a company that has introduced product innovation using breakthrough technologies. The award recognizes the added value, the benefits of the product and the return on investment it offers to the customer which will lead to increased revenues and market share.
3 תגובות
2018 and still no vaccine
If the company is so good at development, what happens to the stock?
Why has the stock been falling for a year?
Thanks
these
A good company with a great future. Keep it up!